90 related articles for article (PubMed ID: 35544051)
41. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial.
Alberer M; Gnad-Vogt U; Hong HS; Mehr KT; Backert L; Finak G; Gottardo R; Bica MA; Garofano A; Koch SD; Fotin-Mleczek M; Hoerr I; Clemens R; von Sonnenburg F
Lancet; 2017 Sep; 390(10101):1511-1520. PubMed ID: 28754494
[TBL] [Abstract][Full Text] [Related]
42. Phase III clinical trials comparing the immunogenicity and safety of the vero cell-derived Japanese encephalitis vaccine Encevac with those of mouse brain-derived vaccine by using the Beijing-1 strain.
Miyazaki C; Okada K; Ozaki T; Hirose M; Iribe K; Yokote H; Ishikawa Y; Togashi T; Ueda K
Clin Vaccine Immunol; 2014 Feb; 21(2):188-95. PubMed ID: 24334689
[TBL] [Abstract][Full Text] [Related]
43. Safety and immunogenicity of co-administered hookworm vaccine candidates Na-GST-1 and Na-APR-1 in Gabonese adults: a randomised, controlled, double-blind, phase 1 dose-escalation trial.
Adegnika AA; de Vries SG; Zinsou FJ; Honkepehedji YJ; Dejon Agobé JC; Vodonou KG; Bikangui R; Bouyoukou Hounkpatin A; Bache EB; Massinga Loembe M; van Leeuwen R; Molemans M; Kremsner PG; Yazdanbakhsh M; Hotez PJ; Bottazzi ME; Li G; Bethony JM; Diemert DJ; Grobusch MP;
Lancet Infect Dis; 2021 Feb; 21(2):275-285. PubMed ID: 32926834
[TBL] [Abstract][Full Text] [Related]
44. Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial.
Kumar Rai G; Saluja T; Chaudhary S; Tamrakar D; Kanodia P; Giri BR; Shrestha R; Uranw S; Kim DR; Yang JS; Park IY; Kyung SE; Vemula S; Reddy E J; Kim B; Gupta BP; Jo SK; Ryu JH; Park HK; Shin JH; Lee Y; Kim H; Kim JH; Mojares ZR; Wartel TA; Sahastrabuddhe S
Lancet Infect Dis; 2022 Apr; 22(4):529-540. PubMed ID: 34942090
[TBL] [Abstract][Full Text] [Related]
45. Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children.
Janewongwirot P; Puthanakit T; Anugulruengkitt S; Jantarabenjakul W; Phasomsap C; Chumket S; Yoksan S; Pancharoen C
Vaccine; 2016 Oct; 34(44):5279-5283. PubMed ID: 27628323
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.
Kremsner PG; Ahuad Guerrero RA; Arana-Arri E; Aroca Martinez GJ; Bonten M; Chandler R; Corral G; De Block EJL; Ecker L; Gabor JJ; Garcia Lopez CA; Gonzales L; Granados González MA; Gorini N; Grobusch MP; Hrabar AD; Junker H; Kimura A; Lanata CF; Lehmann C; Leroux-Roels I; Mann P; Martinez-Reséndez MF; Ochoa TJ; Poy CA; Reyes Fentanes MJ; Rivera Mejia LM; Ruiz Herrera VV; Sáez-Llorens X; Schönborn-Kellenberger O; Schunk M; Sierra Garcia A; Vergara I; Verstraeten T; Vico M; Oostvogels L;
Lancet Infect Dis; 2022 Mar; 22(3):329-340. PubMed ID: 34826381
[TBL] [Abstract][Full Text] [Related]
47. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial.
Madhi SA; Cutland CL; Jose L; Koen A; Govender N; Wittke F; Olugbosi M; Meulen AS; Baker S; Dull PM; Narasimhan V; Slobod K
Lancet Infect Dis; 2016 Aug; 16(8):923-34. PubMed ID: 27139805
[TBL] [Abstract][Full Text] [Related]
48. High titre neutralising antibodies to influenza after oral tablet immunisation: a phase 1, randomised, placebo-controlled trial.
Liebowitz D; Lindbloom JD; Brandl JR; Garg SJ; Tucker SN
Lancet Infect Dis; 2015 Sep; 15(9):1041-1048. PubMed ID: 26333337
[TBL] [Abstract][Full Text] [Related]
49. Immunogenicity and safety of the inactivated Japanese encephalitis vaccine IXIARO® in elderly subjects: Open-label, uncontrolled, multi-center, phase 4 study.
Cramer JP; Dubischar K; Eder S; Burchard GD; Jelinek T; Jilma B; Kollaritsch H; Reisinger E; Westritschnig K
Vaccine; 2016 Aug; 34(38):4579-4585. PubMed ID: 27460550
[TBL] [Abstract][Full Text] [Related]
50. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial.
Zhu FC; Wurie AH; Hou LH; Liang Q; Li YH; Russell JB; Wu SP; Li JX; Hu YM; Guo Q; Xu WB; Wurie AR; Wang WJ; Zhang Z; Yin WJ; Ghazzawi M; Zhang X; Duan L; Wang JZ; Chen W
Lancet; 2017 Feb; 389(10069):621-628. PubMed ID: 28017399
[TBL] [Abstract][Full Text] [Related]
51. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial.
Nicholson KG; Abrams KR; Batham S; Clark TW; Hoschler K; Lim WS; Medina MJ; Nguyen-Van-Tam JS; Read RC; Warren FC; Zambon M
Lancet Infect Dis; 2011 Feb; 11(2):91-101. PubMed ID: 21168369
[TBL] [Abstract][Full Text] [Related]
52. Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.
Sáez-Llorens X; Tricou V; Yu D; Rivera L; Tuboi S; Garbes P; Borkowski A; Wallace D
Lancet Infect Dis; 2017 Jun; 17(6):615-625. PubMed ID: 28365225
[TBL] [Abstract][Full Text] [Related]
53. Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity.
Nasveld PE; Marjason J; Bennett S; Aaskov J; Elliott S; McCarthy K; Kanesa-Thasan N; Feroldi E; Reid M
Hum Vaccin; 2010 Nov; 6(11):906-14. PubMed ID: 20864814
[TBL] [Abstract][Full Text] [Related]
54. Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial.
Clarke E; Bashorun A; Adigweme I; Badjie Hydara M; Umesi A; Futa A; Ochoge M; Obayemi D; Edem B; Saidy-Jah E; Onwuchekwa C; Dhere R; Sethna V; Kampmann B; Goldblatt D; Taylor D; Andi-Lolo I; Hosken N; Antony K; Innis BL; Alderson MR; Lamola S
Lancet Infect Dis; 2021 Jun; 21(6):834-846. PubMed ID: 33516293
[TBL] [Abstract][Full Text] [Related]
55. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia.
Logunov DY; Dolzhikova IV; Zubkova OV; Tukhvatullin AI; Shcheblyakov DV; Dzharullaeva AS; Grousova DM; Erokhova AS; Kovyrshina AV; Botikov AG; Izhaeva FM; Popova O; Ozharovskaya TA; Esmagambetov IB; Favorskaya IA; Zrelkin DI; Voronina DV; Shcherbinin DN; Semikhin AS; Simakova YV; Tokarskaya EA; Lubenets NL; Egorova DA; Shmarov MM; Nikitenko NA; Morozova LF; Smolyarchuk EA; Kryukov EV; Babira VF; Borisevich SV; Naroditsky BS; Gintsburg AL
Lancet; 2020 Sep; 396(10255):887-897. PubMed ID: 32896291
[TBL] [Abstract][Full Text] [Related]
56. Study protocol for a phase 1/2, single-centre, double-blind, double-dummy, randomized, active-controlled, age de-escalation trial to assess the safety, tolerability and immunogenicity of a measles and rubella vaccine delivered by a microneedle patch in healthy adults (18 to 40 years), measles and rubella vaccine-primed toddlers (15 to 18 months) and measles and rubella vaccine-naïve infants (9 to 10 months) in The Gambia [Measles and Rubella Vaccine Microneedle Patch Phase 1/2 Age De-escalation Trial].
Adigweme I; Akpalu E; Yisa M; Donkor S; Jarju LB; Danso B; Mendy A; Jeffries D; Njie A; Bruce A; Royals M; Goodson JL; Prausnitz MR; McAllister D; Rota PA; Henry S; Clarke E
Trials; 2022 Sep; 23(1):775. PubMed ID: 36104719
[TBL] [Abstract][Full Text] [Related]
57. Microneedle technology for potential SARS-CoV-2 vaccine delivery.
McNamee M; Wong S; Guy O; Sharma S
Expert Opin Drug Deliv; 2023 Jun; 20(6):799-814. PubMed ID: 37128730
[TBL] [Abstract][Full Text] [Related]
58. Smart Mushroom-Inspired Imprintable and Lightly Detachable (MILD) Microneedle Patterns for Effective COVID-19 Vaccination and Decentralized Information Storage.
Li Q; Xu R; Fan H; Xu J; Xu Y; Cao P; Zhang Y; Liang T; Zhang Y; Chen W; Wang Z; Wang L; Chen X
ACS Nano; 2022 May; 16(5):7512-7524. PubMed ID: 35451839
[TBL] [Abstract][Full Text] [Related]
59. Safety of inactivated COVID-19 vaccines in autoimmune encephalitis: A real-world cross-sectional survey.
Liu X; Guo K; Lu L; Luo R; Liu J; Zhou D; Hong Z
Mult Scler Relat Disord; 2023 Feb; 70():104495. PubMed ID: 36603293
[TBL] [Abstract][Full Text] [Related]
60. Separable Microneedle Patch to Protect and Deliver DNA Nanovaccines Against COVID-19.
Yin Y; Su W; Zhang J; Huang W; Li X; Ma H; Tan M; Song H; Cao G; Yu S; Yu D; Jeong JH; Zhao X; Li H; Nie G; Wang H
ACS Nano; 2021 Sep; 15(9):14347-14359. PubMed ID: 34472328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
